Condition
T-Acute Lymphoblastic Leukemia
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Unknown1
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07012447Phase 2Recruiting
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
NCT06633354Early Phase 1RecruitingPrimary
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
NCT02763384Phase 2TerminatedPrimary
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
NCT05127135Phase 1UnknownPrimary
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
Showing all 4 trials